NovaBay Pharmaceuticals Inc (B9P.BE)
| Previous close | 0.1240 |
| Open | 0.1240 |
| Bid | 0.0935 x N/A |
| Ask | 0.0990 x N/A |
| Day's range | 0.1240 - 4.3400 |
| 52-week range | 0.1240 - 27.3000 |
| Volume | |
| Avg. volume | 52 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
EMERYVILLE, Calif., May 29, 2024--NovaBay® Pharmaceuticals, Inc. the "Company") (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company’s Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission (the "SEC") were approved by stockholders at its 2024 Annual Meeting of Stockholders held on May 28, 2024. Among the proposals, stockholders approved a reverse stock split and authorized the Company’s Board of Directors to deter
- Business Wire
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
EMERYVILLE, Calif., May 13, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova® product bundles specifically designed to provide easy, affordable and effective solutions for individualized relief from dry eye symptoms. The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of th
- Business Wire
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
EMERYVILLE, Calif., May 09, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.
